Skip to main content

Table 1 Association of RBM3 IHC results and clinico-pathological features of esophageal adenocarcinoma samples

From: Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome

  RBM3 immunohistochemistry
  Analyzable, n Low, % High, % p value
All cancers 268 33.58 66.42  
Age group
 < 65 years 84 65.76 34.24 0.7355
 > 65 years 184 67.86 32.14
Sex
 male 226 33.63 66.37 0.9703
 female 42 33.33 66.67
Tumor stage
 pT1 55 23.64 76.36 0.333
 pT2 28 35.71 64.29
 pT3 163 36.81 63.19
 pT4 20 35 65
UICC stage
 I 52 19.23 80.77 0.0031
 II 36 30.56 69.44
 III 155 34.84 65.16
 IV 24 62.5 37.5
Tumor grading
 G1 14 21.43 78.57 0.6477
 G2 98 35.71 64.29
 G3 150 33.33 66.67
 G4 4 50 50
Resektion margin
 R0 193 34.72 65.28 0.4129
 R1 69 30.43 69.57
 R2 3 66.67 33.33
Lymph node metastasis
 N0 82 24.39 75.61 0.1623
 N1 43 34.88 65.12
 N2 65 41.54 58.46
 N3 75 34.67 65.33
Distant metastasis
 M0 244 30.74 69.26 0.0024
 M1 24 62.5 37.5